6. RIFERIMENTI BIBLIOGRAFICI
Aasa-Chapman M.M., Hayman A., Newton P., Cornforth D., Williams I., Borrow P., Balfe P., McKnight A. (2004). Development of the antibody response in acute HIV-1 infection. AIDS. 18(3): 371-81.Bendinelli M., Pistello M., Del Mauro D., Cammarota G., Maggi F., Leonildi A., Giannecchini S., Bergamini C., Matteucci D. (2001). During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein. J. Virol. 75: 4584-93.
Bigornia L., Lockridge K.M., Sparger E.E. (2001). Construction and in vitro characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses. J.Virol. 75: 1054-60.
Cao H., Tamilarasu N., Rana T. M. (2006). Orientation and affinity of HIV-1 Tat fragments in Tat-TAR complex determined by fluorescence resonance energy transfer.
Bioconjug. Chem. 17: 352-8.
Chatterji U., Grant C.K., Elder J.H. (2000). Feline immunodeficiency virus Vif localizes to the nucleus. J. Virol. 74: 2533-40.
Chatterji U., De Parseval A., Elder J.H. (2002). Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators. J. Virol. 76: 9624-34.
Chiu L., Greene S. (2006). Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends in Immunol. 27: 291-297.
Cohen J. (2007). AIDS research. Did Merck's failed HIV vaccine cause harm? Science. 318: 1048-1049.
Conticello S.G., Harris R.S., Neuberger M.S. (2003). The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13: 2009-2013.
Davis K.L, Gray E.S, Moore P.L., Decker J.M., Salomon A., Montefiori D.C., Graham B.S., Keefer M.C., Pinter A., Morris L., Hahn B.H., Shaw G.M. (2009). High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing
De Parseval A., Chatterji U., Sun P., Elder J.H. (2004). Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. PNAS. 101: 13044-13049.
Derdeyn C.A., Decker J.M, Bibollet-Ruche F., Mokili J. L., Muldoon M., Denham S. A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., Hunter E. (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 303: 2019–2022.
Dunham S.P. (2006). Lessons from the cat: development of vaccines against lentiviruses.
Vet. Immunol. Immunopathol. 112: 67-77.
Elder J.H., Sundstrom M., De Rozieres S., De Parseval A., Grant C.K., Lin Y.C (2008). Molecular mechanisms of FIV infection. Vet. Immunol. Immunopathol. 123(1-2): 3-13.
Flynn J.N., Dunham S., Mueller A., Cannon C., Jarrett O. (2002). Involvement of cytolytic and non-cytolytic T cells in the control of feline immunodeficiency virus infection. Vet. Immunol. Immunopathol. 85(3-4): 159-70.
Franca R., Spadari S., Maga G. (2006). APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism. Med. Sci. Monit. 12: 92-98.
Garg, H., Fuller F.J., Tompkins W.A. (2004). Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion. Virology. 321: 274-86.
Gemeniano M.C, Sawai E.T., Leutenegger C.M., Sparger E.E. (2003). Feline immunodeficiency virus ORF-A is required for virus particle formation and virus infectivity. J. Virol. 77: 8819-30.
Gemeniano M.C., Sawai E.T, Sparger E.E. (2004). Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology. 325(2): 167-74.
Ghazawi A., Mustafa F., Phillip P.S., Jayanth P., Ali J., Rizvi T.A. (2006). Both the 5' and 3' LTRs of FIV contain minor RNA encapsidation determinants compared to the two core packaging determinants within the 5' untranslated region and gag. Microbes Infect. 8: 767-78.
Granados-González V., Piedrahita L.D., Martínez M., Genin C., Riffard S., Urcuqui-Inchima S. (2009). Role of the HIV-1 V1/V2 domains in the induction of neutralizing antibodies. Enfer. Infec. Microbi.l Clin.
Gray E.S., Moore P.L., Choge I.A., Decker J.M., Bibollet-Ruche F., Li H., Leseka N., Treurnicht F., Mlisana K., Shaw G.M., Karim S.S., Williamson C., Morris L. (2007). Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 12: 6187-96.
Harris R.S., Liddament M.T. (2004). Retroviral restriction by APOBEC proteins. Nat.
Rev. Immunol. 4: 868-877.
Hogan T.H., Stauff D.L., Krebs F.C., Gartner S., Quiterio S.J., Wigdahl B. (2003). Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression. J. Neurovirol. 9: 55-68.
Hu S.L., Stamatatos L. (2007). Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5(6): 507-13.
Jerome K.R., Sloan D.D., Aubert M. (2003). Measurement of CTL-induced cytotoxicity: the caspase 3 assay. Apoptosis. 8: 563-71.
Jewell N.A., Mansky L.M. (2000). In the beginning: genome recognition, RNA encapsidation and the initiation of complex retrovirus assembly. J. Gen. Virol. 81: 1889-99.
Kanzaki L.I., Looney D.J. (2004). Feline immunodeficiency virus: a concise review.
Front. Biosci. 9: 370-7.
Kinter A.L., Horak R., Sion M., Riggin L., McNally J., Lin Y., Jackson R., O'shea A., Roby G., Kovacs C., Connors M., Migueles S.A., Fauci A.S. (2007). CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res. Hum.
Retroviruses. 23(3): 438-50.
Lecossier D., Bouchonnet F., Clavel F., Hance A.J. (2003). Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300: 1112.
Lin Y.C., Beck Z., Morris G.M., Olson A.J., Elder J.H. (2003). Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J. Virol. 77: 6589-600.
Little S., Sears W., Lachtara J., Bienzle D. (2009). Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in Canada. Can. Vet. J. 50(6): 644-8.
Manrique M.L., Rauddi M.L., Gonzalez S.A., Affranchino J.L. (2004) A. Functional domains in the feline immunodeficiency virus nucleocapsid protein. Virology. 327: 83-92. Manrique M.L., Gonzalez S.A., Affranchino J.L. (2004) B. Functional relationship between the matrix proteins of feline and simian immunodeficiency viruses. Virology. 329: 157-67.
Mascola J.R. (2003). Defining the protective antibody response for HIV-1. Curr. Mol.
Med. 3: 209-216.
Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., Montefiori D.C. (2005). Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.
J. Virol. 79(16): 10103-7.
Matteucci D., Mazzetti P., Baldinotti F., Zaccaro L., Bendinelli M. (1995). The feline lymphoid cell line MBM and its use for feline immunodeficiency virus isolation and quantitation. Vet. Immunol. Immunopathol. 46: 71-82.
McBurney S.P., Young K.R., Nwaigwe C.I., Soloff A.C., Cole K.S., Ross T.M. (2006). Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.
Curr. HIV Res. 4: 475-84.
McMichael A.J. (2006). HIV vaccines. Annu. Rev. Immunol. 24: 227-255.
Miller D.L., Taylor S.K., Rotstein D.S., Pough M.B., Barr M.C., Baldwin C.A., Cunningham M., Roelke M., Ingram D. (2006). Feline Immunodeficiency Virus and Puma Lentivirus in Florida panthers (Puma concolor coryi): Epidemiology and Diagnostic Issues. Vet. Res. Commun. 30: 307-17.
Montefiori D. C. (2004). Evaluating neutralizing antibodies against HIV, SIV and SHIV in a luciferase reporter gene assay, p. 12.11.1–12.11.15. In J. E.Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, and R. Coico (ed.), Current protocols in immunology. John Wiley & Sons, New York, N.Y.
Montefiori D.C., Morris L., Ferrari G., Mascola J.R. (2007). Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Curr. Opin. HIV AIDS. 2: 169-176.
Montefiori D.C. (2009). Measuring HIV neutralization in a luciferase reporter gene assay.Methods Mo.l Biol. 485: 395-405.
Moscardini M., Pistello M., Bendinelli M., Ficheux D., Miller J.T., Gabus C., Le Grice S.F., Surewicz W.K., Darlix J.L. (2002). Functional interactions of nucleocapsid protein of feline immunodeficiency virus and cellular prion protein with the viral RNA. J.
Mol. Biol. 318: 149-59.
Motokawa K., Hohdatsu T., Imori A., Arai S., Koyama H. (2005). Mutations in feline immunodeficiency (FIV) virus envelope gene V3-V5 regions in FIV-infected cats. Vet.
Microbiol. 106: 33-40.
Mustafa F., Ghazawi A., Jayanth P., Phillip P.S., Ali J., Rizvi T.A. (2005). Sequences intervening between the core packaging determinants are dispensable for maintaining the packaging potential and propagation of feline immunodeficiency virus transfer vector RNAs. J. Virol. 79: 13817-21.
Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272: 263-7.
Natoli E., Baggio A., Pontier D. (2001). Male and female agonistic and affiliative relationships in a social group of farm cats (Felis catus L.). Behav Processes. 53: 137-143.
Obert L.A, Hoover E.A. (2000). Feline immunodeficiency virus clade C mucosal transmission and disease courses. AIDS Res. Hum. Retrov. 16: 677–88.
Operario D.J., Reynolds H.M., Kim B. (2005). Comparison of DNA polymerase activities between recombinant feline immunodeficiency and leukemia virus reverse transcriptases. Virology. 335: 106-21.
Paul T.A., Casey J.W., Avery R.J., Sutton C.A. (2006). Expression of feline immunodeficiency virus Vif is associated with reduced viral mutation rates without restoration of replication of vif mutant viruses. Virology. 361(1): 112-22.
Payne S.L., Elder J.H. (2001). The role of retroviral dUTPases in replication and virulence. Curr. Protein. Pept. Sci. 2: 381-8.
Pedersen N.C., Ho E.W., Brown M.L., Yamamoto J.K. (1987). Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.
Science. 235: 790-3.
Phadke A.P., Choi I.S., Li Z., Weaver E., Collisson E.W. (2004). The role of inducer cells in mediating in vitro suppression of feline immunodeficiency virus replication.
Pikora C.A. (2004). Glycosylation of the ENV spike of primate immunodeficiency viruses and antibody neutralization. Curr. HIV Res. 2(3): 243-54.
Pistello M., Moscardini M., Mazzetti P., Bonci F., Zaccaro L., Isola P., Freer G. Specter S., Matteucci D., Bendinelli M. (2002). Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and vivo characterization.
Virology. 298: 84-95.
Richman D.D. (2003). Rapid evolution of the neutralizing antibody response to HIV type infection. Proc. Natl. Acad. 100: 4144-4149.
Rudd P.M., Elliott T., Cresswell P., Wilson I.A., Dwek R.A. (2001). Glycosylation and the immune system. Science. 291(5512): 2370-6.
Saenz D.T., Poeschla E.M. (2004). FIV: from lentivirus to lentivector. J. Gene Med. 1: 95-104.
Sauter S.L., Gasmi M. (2001). FIV vector systems. Somat. Cell. Mol. Genet. 26: 99-129. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., Takeuchi Y., Hosie M.J., Willett B.J. (2004). Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science. 303: 1192-5.
Sprague W.S., Robbiani M., Avery P.R., O'Halloran K.P., Hoover E.A. (2008). Feline immunodeficiency virus dendritic cell infection and transfer. J. Gen. Virol. 89(Pt 3): 709-15.
Takaori-Kondo A. (2006). APOBEC family proteins: novel antiviral innate immunity.
Int. J. Hematol. 83(3): 213-6.
Tomonaga K., Mikami T. (1996). Molecular biology of the feline immunodeficiency virus auxiliarygenes. J. Gen. Virol. 77: 1611-21.
Tompkins M.B., Tompkins W.A. (2008). Lentivirus-induced Immune Dysregulation.
Vet. Immunol. Immunopathol. 15: 45-55.
Van der Meer F.J., Schuurman N.M., Egberink H.F. (2007). Feline immunodeficiency virus infection is enhanced by feline bone marrow-derived dendritic cells. J. Gen. Virol. 88(Pt 1): 251-8.
Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. (2003). Antibody neutralization and escape by HIV-1. Nature. 422(6929): 307-12.
Wichroski M.J., Ichiyama K., Rana T.M. (2005). Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280: 8387-8396.
Willett B.J., Cannon C.A., Hosie M.J. (2003). Expression of CXCR4 on feline peripheral blood mononuclear cells: effect of feline immunodeficiency virus infection. J.
Virol. 77: 709-12.
Willett B.J., McMonagle E.L., Ridha S., Hosie M.J. (2006). Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J.
Virol. 80: 3386-94.
Willey S., Aasa-Chapman M.M. (2008). Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol. 16(12): 596-604.
Yang X., Kurteva S., Ren X., Lee S., Sodroski J. (2005). Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J. Virol. 79(19): 12132-47.
Zhang J., Liu X., De Clercq E. (2009). Capsid (CA) protein as a novel drug target: recent progress in the research of HIV-1 CA inhibitors. Mini Rev. Med. Chem. 9(4): 510-8.
Zolla-Pazner S. (2005). Improving on nature: focusing the immune response on the V3 loop. Hum. Antibodies. 14(3-4): 69-72.
